Patients whose first cancer was melanoma in situ had a greater risk of developing subsequent melanoma after 2 years following the first diagnosis compared with patients whose first cancer was invasive melanoma, according to recently published study results.
MRV Research
Wistar-Penn Collaboration Identifies HSP70 as Promising New Target for Melanoma Therapy
While the study of targeted therapies in cancer is a well-established field, it remains an area of incredible promise with ample room for further discoveries. A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70 (HSP70), that we believe could be very helpful in treating patients with melanoma.
New Mouse Cell Line To Study BRAF Melanoma
A team of Dartmouth scientists has developed a cell line that can be used as a research tool for investigators using mice models of melanoma.
In the study, published in Pigment Cell Melanoma Research and titled “Multiple murine BRaf (V600E) melanoma cell lines with sensitivity to PLX4032”, the team designed a protocol that permits the in vitro growth of murine BRAF melanoma cells, that can then be transplanted into mice.
Novel Mechanism Behind Melanoma Drug Resistance Unveiled
Recent research has unveiled the mechanisms responsible for targeted therapy resistance in melanoma patients.
This type of therapy has a lower toxicity rate and can improve results for different types of cancers, bypassing several side effects associated with currently used chemotherapies. Nonetheless, patients usually acquire some degree of resistance to targeted therapies, allowing tumor cells to progress and become more aggressive, eventually acquiring a metastatic phenotype